<DOC>
	<DOCNO>NCT02062463</DOCNO>
	<brief_summary>This study conduct ass whether train participant proper use BF SPIROMAX Symbicort TURBOHALER improve device-handling technique potentially improve treatment outcome , ie , good asthma control .</brief_summary>
	<brief_title>Study Evaluate Mastery Inhaler Technique Budesonide Formoterol ( BF ) SPIROMAX® Compared SYMBICORT® TURBOHALER® Treatment Adult Patients With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Written inform consent sign date adult patient conduct study related procedure . The patient man woman 18 75 year age screen visit . The patient diagnosis asthma accordance Global Initiative Asthma ( GINA ) criterion evidence United Kingdom ( UK ) quality outcome framework approve Read code ( UK diagnostic cod system ) . The patient receive step 3 4 therapy asthma define British Thoracic Society ( BTS ) guideline ( daily dose BDPequivalent inhale corticosteroid ( ICS ) ≥800 mcg 2000 mcg part fix free combination longacting betaagonists ( LABA ) . If patient female childbearing potential ( postmenarche le 2 year postmenopausal surgically sterile ) patient must willing commit use medically accept method contraception duration study 30 day discontinue study drug . The patient , judge investigator , must willing able understand risk benefit study participation give inform consent comply study requirement specify protocol entire duration study participation . The patient SPIROMAX TURBOHALER naïve ( use TURBOHALER device last 6 month , minimize carryover prior device use ) . If female , patient must negative urine pregnancy test . criterion apply , please contact investigator additional information The patient clinically significant uncontrolled medical condition ( treat untreated ) , judgment investigator , cause participation study detrimental patient . The patient participate Teva sponsor clinical study BF SPIROMAX last 6 month . The patient pregnant , attempt become pregnant , breast feeding . ( Any woman become pregnant study withdrawn study . ) The patient use clinical trial investigational drug within 1 month screen visit . The patient ongoing asthma exacerbation receive OCS and/or antibiotic low respiratory condition ( proxy measure identify asthma exacerbation and/or low respiratory infection , suggestive alter inspiratory capability ) 2 week precede visit The patient currently receive OCS ( include long short course ) . The patient significant chronic low respiratory tract disease asthma eg chronic obstructive pulmonary disease ( COPD ) , cystic fibrosis interstitial lung disease . Conditions predominant , minor degree bronchiectasis , reason exclusion . The patient know allergy severe sensitivity constituent study drug ( SPIROMAX TURBOHALER ) eg , lactose milk protein . criterion apply , please contact investigator additional information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Asthma</keyword>
</DOC>